Could a cancer drug help lung damage after transplant?
NCT ID NCT03674047
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tests the drug ruxolitinib (Jakafi) in 50 people who developed bronchiolitis obliterans syndrome (BOS) after a stem cell transplant. BOS is a serious lung condition that causes scarring and breathing problems. The goal is to see if ruxolitinib can improve lung function and control the disease by reducing inflammation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ruxolitinib (also known as Jakafi)
What this could lead to
If successful, this could offer a new treatment option to improve lung function and slow disease progression in patients with bronchiolitis obliterans syndrome after transplant.
What could go wrong
This is a small, early-phase study with only 50 participants. The drug may not work for everyone, and side effects like infection or blood issues are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OTHER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Cancer Center
Duarte, California, 91010, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
H. Lee Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States